Details for Patent: 9,156,823

Title:	Antiviral compounds
Abstract:	The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s):	Bacon; Elizabeth M. (Burlingame, CA), Cottell; Jeromy J. (Redwood City, CA), Katana; Ashley Anne (San Mateo, CA), Kato; Darryl (San Francisco, CA), Krygowski; Evan S. (Washington, DC), Link; John O. (San Francisco, CA), Taylor; James (San Mateo, CA), Tran; Chinh Viet (San Diego, CA), Martin; Teresa Alejandra Trejo (Union City, CA), Yang; Zheng-Yu (Palo Alto, CA), Zipfel; Sheila (San Mateo, CA)
Assignee:	Gilead Pharmasset LLC (Foster City, CA)
Filing Date:	Nov 16, 2011
Application Number:	13/884,578
Claims:	1. A compound of formula (I): E.sup.1a-V.sup.1a--C(.dbd.O)--P.sup.1a--W.sup.1a--P.sup.1b--C(.dbd.O)--V.- sup.1b-E.sup.1b (I) wherein: W.sup.1a is ##STR02356## optionally substituted with one or more groups independently selected from the group consisting of halo, alkyl, haloalkyl, and cyano; X.sup.11 is --CH.sub.2--CH.sub.2--, --O--CH.sub.2--, or --CH.dbd.CH--; E.sup.1a is --N(H)(alkoxycarbonyl), --N(H)(cycloalkylcarbonyl) or --N(H)(cycloalkyloxycarbonyl); or E.sup.1a-V.sup.1a taken together are R.sup.9a; E.sup.1b is --N(H)(alkoxycarbonyl), --N(H)(cycloalkylcarbonyl) or --N(H)(cycloalkyloxycarbonyl); or E.sup.1b-V.sup.1b taken together are R.sup.9b; V.sup.1a and V.sup.1b are each independently selected from the group consisting of: ##STR02357## one of P.sup.1a and P.sup.1b is ##STR02358## and the other of P.sup.1a and P.sup.1b is selected from the group consisting of: ##STR02359## R.sup.9a and R.sup.9b are each independently: ##STR02360## or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 wherein at least one of E.sup.1a and E.sup.1b is --N(H)C(.dbd.O)OCH.sub.3. 3. The compound of claim 1 wherein both of E.sup.1a and E.sup.1b are --N(H)C(.dbd.O)OCH.sub.3. 4. The compound of claim 1 wherein at least one of V.sup.1a and V.sup.1b is selected from the group consisting of: ##STR02361## 5. The compound of claim 1 wherein at least one of V.sup.1a and V.sup.1b is: ##STR02362## 6. The compound of claim 1 wherein at least one of V.sup.1a and V.sup.1b is selected from the group consisting of: ##STR02363## 7. The compound of claim 1 wherein V.sup.1a and V.sup.1b are each independently selected from the group consisting of: ##STR02364## 8. The compound of claim 1 wherein at least one of P.sup.1a and P.sup.1b is selected from the group consisting of: ##STR02365## 9. The compound of claim 1 wherein P.sup.1a and P.sup.1b are each independently selected from the group consisting of: ##STR02366## 10. A compound selected from the group consisting of: ##STR02367## ##STR02368## ##STR02369## ##STR02370## ##STR02371## ##STR02372## ##STR02373## ##STR02374## ##STR02375## ##STR02376## ##STR02377## ##STR02378## ##STR02379## ##STR02380## ##STR02381## ##STR02382## ##STR02383## ##STR02384## ##STR02385## ##STR02386## ##STR02387## 11. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier. 12. The pharmaceutical composition of claim 11, further comprising at least one therapeutic agent. 13. The pharmaceutical composition of claim 12, wherein said therapeutic agent is a ribavirin analog, NS3 protease inhibitor, NS5b polymerase inhibitor, alpha-glucosidase 1 inhibitor, hepatoprotectant, non-nucleoside inhibitor of HCV, or other drug for treating HCV. 14. The pharmaceutical composition of claim 11, further comprising a nucleoside analogue. 15. The pharmaceutical composition of claim 14, wherein said nucleoside analogue is selected from the group consisting of ribavirin, viramidine, levovirin, a L-nucleoside, and isatoribine. 16. A method of treating hepatitis C virus in a human patient in need thereof, said method comprising administering to the patient a pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.